At Carolina Blood and Cancer Care Associates, the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing equitable access to care.
At Carolina Blood and Cancer Care Associates, where Sashi Naidu, MD, is director of research, the No One Left Alone (NOLA) initiative, first implemented in January 2021, is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing their equitable access to care.
Transcript
Can you discuss the NOLA initiative from Carolina Blood and Cancer Care Associates?
NOLA was conceived by our need at our practice. There are a lot of foundations and opportunities for patient access, but it’s often a fragmented process. So the purpose of NOLA was to bring that process in house, where the patients can feel comfortable that the physicians who are their treating doctors are taking care of this aspect of their health care, which often can be a very big challenge—even sometimes more than the clinical aspects of their cancer care.
What is the status of patient assistance initiatives for oral cancer drugs within NOLA?
We picked up oral financial assistance initiatives just like the intravenous drugs. It’s a seamless process. As with many community oncology practices, there is an oral dispensary in house. It is a just a very easy transition to add oral financial assistance to our intravenous drug financial assistance. So there’s not been any major problems there.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
The study found significant disparities in the exposure to contaminants. Communities with higher percentages of Hispanic and Black residents were not only more likely to have unregulated chemicals in their drinking water, but they were also more frequently located near pollution sources.
Read More
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More